- Table of Contents
We validate the specificity of these antibodies to Suv39h2 by testing them on tissues known to express Suv39h2 positively and negatively. Browse below to find the Suv39h2 antibody that suites your experiment. We have 4 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Histone-lysine N-methyltransferase SUV39H2.
H3'Lys-9' trimethylation is also required to direct DNA methylation at pericentric repeats. SUV39H1 is targeted to histone H3 via its interaction with RB1 and is involved in several processes, such as cell cycle regulation, transcriptional repression and regulation of telomere length.
|class V-like SAM-binding methyltransferase superfamily|
FLJ23414Histone H3-K9 methyltransferase 2; H3-K9-HMTase 2; histone-lysine N-methyltransferase SUV39H2; KMT1BEC 22.214.171.124; Lysine N-methyltransferase 1B; Su(var)3-9 homolog 2; suppressor of variegation 3-9 homolog 2 (Drosophila); Suppressor of variegation 3-9 homolog 2
|Location:||2 A1|2 1.95 cM|
Testis specific; predominant expression in type B spermatogonia and preleptotene spermatocytes.
The multifaceted SUV39H2 antiserum produced by Steven Boster is an excellent tool for applications in biological research. Its high-affinity antibodies have been well-cited and are trusted by the research community. Additionally, it has been validated on Western Blotting, Immunohistochemistry, and ELISA. Boster offers the largest range of SUV39H2 antibodies which means you can be certain that the antibody you choose will work well for your study.
The SUV39H2 gene is associated with a variety of mutations that contribute to its role in cancer. Understanding the role of this mutation in cancer progression is crucial for developing efficient molecular treatments and understanding the nature of the disease. Gene infographics for SUV39H2 include information about mutations in this gene as well as its role in the development of cancer. This information is meant to aid researchers and doctors in understanding the role played by this marker in the fight against cancer.
The poor prognosis can be attributed with increased expression of the SUV39H2 genes in BC metastases and primary tumor cells. While mutations in the SUV39H2 gene are not common in other epithelial cancers, an investigation in a BC cell line has revealed a significant association between the SUV39H2 mRNA level and a poor prognosis. Furthermore, this gene is involved in the regulation of hormones in tumorigenesis, metastasis, and tumorigenesis. It is therefore a potential independent predictor of survival in BC patients suffering from advanced diseases.
Researchers have discovered that SUV39H2 plays a pivotal role in colorectal cancer cells proliferation and metastasis. Its overexpression promotes tumorigenesis and encourages the growth of colorectal cancer. Additionally, the SUV39H2 gene regulates the expression of other genes, such as SLIT1, KCTD12, and GUCA2A. The overexpression of these genes can increase the risk for CRC.
Several studies have also found that patients who have the 1624C variant of the SUV39H2 gene are at a higher risk of developing squamous cells carcinoma. The research also shows that these genes are linked with the emergence of the recurrence of tumors. However, more research is needed to validate this association. The SUV39H2 gene is a key marker in the field.
Numerous studies have also revealed that the TNM stage of stomach cancer is associated with the overexpression of the SUV39H2 gene. Additionally, it is associated with an unfavorable prognosis and a higher HR and later TNM staging. These findings could have implications for cancer treatment. Researchers are hoping to uncover more genetic markers in the near future and apply them to clinical trials. The next step in the quest for more efficient treatments is to enhance the quality of life and quality of cancer patients.
The SUV39H2 gene, which is an oncogenic histone Lysine methyltransferase is a gene related to heterochromatin. It is a key factor in the development and maintenance of heterochromatin. It also regulates DNA methylation at the pericentric repeats. It interacts with G9a and RB1 proteins, which may alter its expression. The SUV39H2 gene is essential in a variety of processes but is most relevant in the creation of heterochromatin.
The SUV39H2 protein was identified by HA or FLAG to indicate the presence of the SUV39H2 gene. The SUV39H2 protein was also co-expressed with the LSD1 and histone H3 proteins. Cells were removed from RIPA buffer and then immunoprecipitated using an affinity gel that was anti-FLAG. After that Western blotting was utilized to determine the relationship between the endogenous histone h3 and exogenous SUV39H2 proteins.
The SUV39H2 marker was chosen due to its specificity in the methylation of lysine residues in the P0 position. It is highly specific and is widely utilized in biochemical as for immunological research. The marker was previously described and is the best option to detect a variety of molecules. High-affinity primary antibodies using the SUV39H2 marker are available for the immunoblotting research.
The SUV39H2 marker of the suppressor-ofvariegation 3-9 homolog 2, (SUV39H2) was used to construct the antibody. It was characterized by a synthetic peptide. Its specificity is determined through automethylation and alternative splicing. It can detect many ligands, including HIV-1. The SUV39H2 marker was not approved for use by humans.
The study demonstrated that anti-influenza HA bNAbs exhibited a greater affinity for the immunizing strain than the prior-year influenza strain. This suggests that the affinity maturation of these antibodies was stimulated by memory B cells. A series of tests demonstrated that high-affinity primary antibodies were created with the SUV39H2 marker to neutralize HIV-1 antigen.
These studies suggest that SUV39H is an essential component of the SIRT1 pathway during myocardial damage. This is consistent with the fact that SUV39H enhances SIRT1 transrepression in the human myocardium. It appears that the SUV39H2 marker has a significant role in the regulation of this protein. It could also be a basis for new therapies.
Next-generation sequencing can be used to reconstruct the lineages of antibodies. It also helps infer germ-line progenitor sequences. However, the sequences might not be 100% identical to the true unmutated ancestor. Next-generation sequencing allows the detection of mutations in the VL and VH gene segments, even though the original VLJL and VHDJH junctional sequences are not recognized.
SUV39H2 is expressed in lung cancer cell lines A549 as well as LTEP. It is a significant marker of NSCLC and may play a role in the process of transcriptional repression. In cancer, SUV39H2 is overexpressed in lung tissues. It was also discovered to be extremely expressed in lung cancer cell lines A549 and LTEP.
The SUV39H2 protein was initially studied as an antigen , in the absence of hapten. Its response to lysozyme white of hen eggs was a reflection of different stages of maturation of affinity. It was interesting to observe that the increase in somatic mutations that increase affinity was not related to the formation of new hydrogen bonds or salt bridges. The increased affinity was accompanied by a greater shape complementarity at the VH-HEL interface.